|
Age, years [median [IQR])
|
71 (62–76)
|
69 (61–75)
|
0.71
|
|
Sex (n [%])
|
|
Male
|
32 (66.6)
|
33 (86.8)
|
0.043
|
|
Female
|
16 (33.3)
|
5 (13.2)
| |
|
T Stage (n [%])
|
|
≤ pT2
|
15 (31.2)
|
12 (31.6)
|
0.99
|
|
≥ pT3
|
31 (64.6)
|
25 (65.8)
| |
|
Unknown
|
2 (4.2)
|
1 (2.6)
| |
|
N Stage (n [%])
|
|
pN0
|
31 (64.6)
|
25 (65.8)
|
0.91
|
|
≥ pN1
|
17 (35.4)
|
13 (34.2)
| |
|
Grade (n [%])
|
|
G1/2
|
13 (27.1)
|
10 (26.3)
|
0.99
|
|
G3
|
31 (64.6)
|
24 (63.2)
| |
|
Unknown
|
4 (8.3)
|
4 (10.5)
| |
|
Lymphovascular invasion (n [%])
|
|
Positive
|
29 (60.4)
|
25 (65.8)
|
0.43
|
|
Negative
|
17 (35.4)
|
10 (26.3)
| |
|
Unknown
|
2 (4.2)
|
3 (7.9)
| |
|
Carcinoma in situ (n [%])
|
|
Positive
|
6 (12.5)
|
4 (10.5)
|
0.72
|
|
Negative
|
40 (83.3)
|
34 (89.5)
| |
|
Unknown
|
2 (4.2)
|
0
| |
|
Soft-tissue surgical margin (n [%])
|
|
Positive
|
6 (12.5)
|
10 (28.9)
|
0.10
|
|
Negative
|
42 (87.5)
|
28 (71.1)
| |
|
Adjuvant chemotherapy (n [%])
|
|
Yes
|
19 (39.6)
|
11 (72.7)
|
0.30
|
|
No
|
29 (60.4)
|
27 (27.3)
| |
|
Follow-up, months (median [IQR])
|
17.1 (9.0–39.3)
|
27.5 (14.1–40.8)
|
0.049
|
